P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD
ECCO '19 Copenhagen
2019
P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre
ECCO '19 Copenhagen
2019
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
ECCO '19 Copenhagen
2019
P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study
ECCO '19 Copenhagen
2019
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
ECCO '19 Copenhagen
2019
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
ECCO '19 Copenhagen
2019
P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling
ECCO '19 Copenhagen
2019
P490: A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P491: INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel
ECCO '19 Copenhagen
2019
P492: Influence of the interval of time between the first and the second anti-TNF in the response to treatment in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
ECCO '19 Copenhagen
2019
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?
ECCO '19 Copenhagen
2019
P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre
ECCO '19 Copenhagen
2019
P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
ECCO '19 Copenhagen
2019